Semaglutide: Research, Studies & Structure

What is Semaglutide?

Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.

Biological role or research focus

Incretin signaling and appetite regulation.

Brand, formulation, and indication matter. An approved product does not validate a research-use-only version.

Role reference: MedlinePlus: Semaglutide injection ↗

Names you may encounter

Ozempic · Wegovy · Rybelsus

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity: GLP-1 receptor agonist
Main research area: Metabolic and indication-specific outcomes
Evidence featured: Human randomized trial
Source check: October 4, 2026

Source: MedlinePlus: Semaglutide injection ↗

Molecular structure

⤢ Enlarge 2D

2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 56843331 ↗

Mechanism & research rationale

It supports glucose-dependent insulin release, slows stomach emptying, and affects appetite. Separate trials are needed to establish weight, cardiovascular, kidney, or liver outcomes.

Source: MedlinePlus: Semaglutide injection ↗

Clinical uses & product context

The current injection reference includes selected diabetes, weight-management, cardiovascular, kidney, and noncirrhotic MASH contexts. Eligibility and approval attach to the exact product and population; this is not a single unrestricted indication.

Source: MedlinePlus: Semaglutide injection ↗

What does the evidence show?

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2021

STEP 1

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Population / model: 1,961 adults with obesity, or overweight with a weight-related condition, without diabetes.
Study design: Semaglutide versus placebo for 68 weeks, alongside lifestyle intervention.
Main finding: Mean weight change was −14.9% versus −2.4%, a 12.4-percentage-point estimated difference. Gastrointestinal effects were common.
Limits & context: These are average results for a specific injectable regimen and trial population. The study is not a comparison with tirzepatide and cannot validate compounded or research-use products.

Read PubMed abstract ↗Publisher paper ↗

Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity. ↗

Human randomized trial · 2023

SELECT cardiovascular outcomes

Did treatment affect cardiovascular events in people without diabetes?

Population / model: 17,604 adults aged 45 or older with established cardiovascular disease, BMI at least 27, and no history of diabetes.
Study design: Double-blind placebo-controlled trial of the studied semaglutide formulation; mean follow-up 39.8 months.
Main finding: Cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. Hazard ratio 0.80 (95% CI 0.72–0.90). Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%.
How to read it: The observed event proportions differ by 1.5 percentage points. The hazard ratio describes relative event rates over follow-up; it is not a 20-percentage-point absolute reduction.
Limits & context: This population already had cardiovascular disease. The result does not establish the same benefit in every person seeking weight loss or validate unregulated preparations. Funded by Novo Nordisk.

Read PubMed abstract ↗Publisher paper ↗

Source: Lincoff et al. · NEJM · SELECT · 2023 ↗

Human randomized withdrawal trial · 2021

STEP 4 · continuation versus withdrawal

What happened after continuing treatment or switching to placebo?

Population / model: 803 adults without diabetes who completed a 20-week semaglutide run-in and reached the studied maintenance regimen; 902 initially entered run-in.
Study design: Double-blind randomized withdrawal comparison over a further 48 weeks, with lifestyle intervention in both groups.
Main finding: From randomization at week 20 to week 68, weight changed by −7.9% with continued semaglutide versus +6.9% after switching to placebo. Gastrointestinal events occurred in 49.1% versus 26.1%.
How to read it: These changes start at randomization, after the initial run-in loss. They are not percentages measured from the original baseline.
Limits & context: People unable to reach the regimen during run-in were not randomized. This selected population limits generalization to everyone starting treatment. It is not a trial of tapering or an individualized stopping strategy.

Read PubMed abstract ↗Publisher paper ↗Free full text ↗

Source: Rubino et al. · JAMA · STEP 4 · 2021 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Search additional PubMed records ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Safety & precautions

Key precautions

Gastrointestinal effects, dehydration, gallbladder and pancreatic problems, retinopathy considerations, and thyroid-tumor warnings require review. Other glucose-lowering medicines can alter hypoglycemia risk.

Source: MedlinePlus: Semaglutide injection ↗

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

What are people discussing?

Fouad Abiad Media

Comparing metabolic peptides in conversation

The speakers compare personal experiences and describe differences among semaglutide, tirzepatide, and retatrutide. Their tolerability anecdotes are not a head-to-head clinical trial.

Question to take to the evidence

Does a comparative trial support the claimed difference in effectiveness or adverse effects?

▶ Watch 10:38–12:06 ↗

Caption excerpt reviewed · Claims not independently verified · 2026-10-04
Original episode: RETATRUTIDE: EVERYTHING YOU NEED TO KNOW | Wes Christensen | Fouad Abiad's Real Bodybuilding Podcast

Watch the source discussions

434 matching video records · 7 with captions indexed.

Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.